Latest News
Orion Pharma launches Phase 1b/2 TEADCO trial of ODM-212 in advanced solid tumours
23 April 2026 - Finnish pharmaceutical company Orion Corporation (Orion Pharma) (HEL:ORNBV) said on Thursday that it has initiated the TEADCO Phase 1b/2 basket trial evaluating ODM-212, an oral pan-TEAD inhibitor, in combination with standard-of-care...
FDA expands Sanofi and Regeneron's Dupixent approval to younger children with chronic spontaneous urticaria
23 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced late Wednesday that the US Food and Drug Administration has approved Dupixent (...
WuXi Biologics gains MFDS approval for three Wuxi manufacturing sites
...
OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product
23 April 2026 - Blood and cell products and services company OrganaBio LLC and RxMP Therapeutics Inc, a late pre-clinical development stage therapeutics company developing novel therapies for the rapid control of severe haemorrhage, on Wednesday anno...
Université Laval and Glycovax Pharma agree exclusive global licence to develop innovative galectin-3 inhibitors
23 April 2026 - Canadian biopharmaceutical company Glycovax Pharma Inc announced on Wednesday an exclusive global licence agreement with Université Laval in Quebec, granting Glycovax the rights to develop and commercialise a family of compound...